28 August 2025 | 2:23AM HKT Giant Biogene Holding (2367.HK) Earnings review: 1H25 sales/NI inline with OP beat on better managed ROI; Guidance unchanged; Buy 2367.HK 12m Price Target: HK$71.00 Price: HK$54.85 Upside: 29.4% | | 12/24 | 12/25E | 12/26E | 12/27E | | --- | --- | --- | --- | --- | | Revenue (Rmb mn) New | 5,538.8 | 6,920.8 | 8,782.7 | 10,406.4 | | Revenue (Rmb mn) Old | 5,538.8 | 6,933.6 | 8,787.7 | 10,360.5 | | EBITDA (Rmb mn) | 2,331.1 | 2,698.1 | 3,331.7 | 3,896.8 | | EPS (Rmb) New | 2.10 | 2 ...

Core Viewpoint - The article discusses the "Action Plan for Promoting High-Quality Development of the Biological Manufacturing Industry in Hainan Province (2025-2027)", which aims to enhance the biological manufacturing sector in Hainan through a structured development path focusing on marine biological manufacturing and breeding [1][2]. Group 1: Development Strategy - The "5+8+N" development path emphasizes two main areas: marine biological manufacturing and biological breeding, targeting five key sectors: biomedicine, biological food, biological agriculture, biological materials, and biological chemicals and energy [2][3]. - The plan includes establishing an innovation center for marine biological manufacturing by the end of this year and aims to cultivate several flagship products and key industrial chain projects [2][3]. Group 2: Advantages of Hainan - Hainan possesses unique advantages for developing the marine biological manufacturing industry, including rich marine resources, favorable policies from the free trade port, established platforms for deep-sea biological development, and a solid industrial foundation with a nearly 800 billion yuan output in high-end food processing and biomedicine [3][4]. - The province plans to develop marine bio-based materials using resources like blue and red algae to produce materials such as polylactic acid and carrageenan fibers [3]. Group 3: Future Goals - By the end of 2027, Hainan aims to create a "dual-core, dual-wing, multi-point" industrial spatial layout centered around Haikou and Sanya, with the goal of achieving over 100 billion yuan in biological manufacturing output and enhancing the overall quality of the industry [4][5].